Best Buys for a Biotech Bubble
There has been a lot of buzz in recent days about the idea of a bubble in the biotech space on the market today. The iShares NASDAQ Biotechnology Index , an ETF that tracks a range of companies in the biotech space, peaked exactly a month ago, and has since lost 12% of its value, falling 3% in a single day yesterday. Investors are understandably concerned that the sell-off will lead to a continued decline in the days ahead.
In this video, Motley Fool health-care analyst David Williamson discusses why there may be some validity to the speculation of a bubble in this sector at the moment. David then gives investors his three top picks for which companies he would jump in on if a biotech pullback offered a lower price point, and why these three pharmaceutical businesses have the underlying strength to survive any market condition.
3 stocks poised to help you retire rich
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.
The article Best Buys for a Biotech Bubble originally appeared on Fool.com.
David Williamson owns shares of Merck. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.